Experimental pill ICP-723 enters human trials for Hard-to-Treat cancers

NCT ID NCT04685226

Recruiting now Disease control Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests an experimental oral drug called ICP-723 in people with advanced solid tumors that cannot be removed by surgery. The trial includes both adults and adolescents (ages 12 and up). The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 310 participants will take part across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ICP-723 (an experimental oral tablet)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that are hard to treat.
What could go wrong: This is an early-phase trial (Phase I/II) focused on safety and dosing, so it is not yet known if ICP-723 will effectively shrink tumors or improve survival. Side effects are possible and being closely monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS

Contacts and locations

Locations

Affiliated Cancer Hospital of Shandong First Medical University
RECRUITING

Jinan, Shandong, China
Affiliated Hospital of Jiangnan University
RECRUITING

Wuxi, Jiangsu, 214000, China
Affiliated Hospital of Qingdao University
RECRUITING

Qingdao, Shandong, 266000, China
Cancer Hospital Affiliated to Guangzhou Medical University
RECRUITING

Guangzhou, Guangdong, 510000, China
Cancer Hospital Affiliated to Harbin Medical University
RECRUITING

Harbin, Heilongjiang, 150000, China
Henan Cancer Hospital
RECRUITING

Zhengzhou, Henan, 450000, China
Henan Provincial People's Hospital
RECRUITING

Zhengzhou, Henan, 450000, China
Hunan Cancer hospital
RECRUITING

Changsha, Hunan, 410000, China
Jiangsu Provincial People's Hospital
RECRUITING

Nanjing, Jiangsu, 210000, China
Peking University Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, 100081, China
Shanxi Cancer Hospital
RECRUITING

Taiyuan, Shanxi, 030000, China
Shijiazhuang People's Hospital
RECRUITING

Shijiazhuang, Hebei, 050000, China
Sun Yat-Sen University Cancer Center
RECRUITING

Guangdong, Guangzhou, 510060, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITING

Guangzhou, Guangdong, 510000, China
The Fifth Affiliated Hospital of Sun Yat-sen University
RECRUITING

Zhuhai, Guangdong, 519000, China
The First Affiliated Hospital of Henan University of Science and Technology
RECRUITING

Luoyang, Henan, 471000, China
The First Affiliated Hospital of Nanchang University
RECRUITING

Nanchang, Jiangxi, 330000, China
The First Affiliated Hospital of Zhengzhou University
RECRUITING

Zhengzhou, Henan, 450000, China
The First Medical Center of the Chinese People's Liberation Army General Hospital
RECRUITING

Beijing, Beijing Municipality, 100081, China
The Second Affiliated Hospital of Anhui Medical University
RECRUITING

Hefei, Anhui, 230000, China
The first affiliated hospital Zhejiang university school of medicine
RECRUITING

Hangzhou, Zhejiang, 310003, China
Union Hospital, Tongji Medical College,Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, 430000, China
Yunnan Cancer Hospital
RECRUITING

Kunming, Yunnan, 650000, China
Zhejiang Cancer Hospital
RECRUITING

Hangzhou, Zhejiang, ,310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.